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Objective: To evaluate the treatment results of patients (pts) with FIGO stage IB2, IIA, IIB cervical carcinoma (CC) treated 
with pre-operative radio-chemotherapy, followed by extended radical hysterectomy.
Methods: Retrospective study of 148 women treated to the Institut Curie for operable FIGO Stage IB2 to IIB, biopsy proved 
CC. Among them, 70 pts, median age 46 years, were treated using the same regimen associating primary radio-cisplatinum 
based chemotherapy, intracavitary LDR brachytherapy, followed by extended radical hysterectomy. Kaplan-Meier estimates 
were used to draw survival curves. Comparisons of survival distribution were assessed by the log-rank test.
Results: Complete histological local-regional response was obtained in 56% of the pts (n = 39). Residual macroscopic or 
microscopic disease in the cervix was observed in 28 pts (40%). All but one had in-situ microscopic residual CC. Lateral 
residual disease in the parametria was also present in 9 pts, all with residual CC. Pelvic lymph nodes were free from micro-
scopic disease in 56 pts (80%). Eight of 55 (11%) radiological N0 patients had microscopic nodal involvement, as compared 
to 6/15 (40%) radiological N1 (p = 0.03). Seventeen pts (25%) had residual cervix disease but negative nodes. After median 
follow-up of 40 months (range, 8–141), 38/70 patients (54.1%) are still alive and free of disease, 6 (8.6%) alive with disease, 
and 11 (15.8%) patients were lost for follow-up but free of disease.
In conclusion: The treatment of locally advanced CC needs a new multidisciplinary diagnostic and treatment approach 
using new therapeutic arms to improve the survival and treatment tolerance among women presenting this disease.
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Introduction
Despite the improvement in management, the survival of advanced stages cervical cancer is still poor 
(1, 2). Most studies showed that the cervical tumor size is a signiﬁ  cant negative prognostic factor and 
is inversely correlated with both survival and time to recurrence (3). Bulky primary tumours with 
diameter over 4 cm in patients with International Federation of Gynaecology and Obstetrics (FIGO) 
stage IB2 to IVa cervical carcinomas are often associated with a higher incidence of nodal metastases 
and distal recurrences (1–3). Nine randomized trials have demonstrated the superiority of combined 
chemotherapy with radiation as compared to radiation alone in the treatment of advanced cervix cancer 
(3–12). The results of these trials demonstrate a consistent improvement in disease-free and overall 
survival. Therefore, the radiotherapy and platinum based chemotherapy was recognized as standard 
treatment for advanced cervical cancer (10). However, the treatment protocols of chemotherapy, volumes 
and doses of radiation therapy, as well as surgical approach varied making difﬁ  cult the comparison of 
the studies (3–12).
As from 1991, Institut Curie progressively introduced concurrent platyl-based chemotherapy in the 
treatment of bulky cervix carcinoma. Treatment policy was also routinely based on lower dose of pre-
operative pelvic irradiation, aiming at decreasing the rate of urinary complications following extended 
radical hysterectomy. This retrospective study was provided to evaluate the treatment results of patients 
with FIGO stage IB2, IIA, IIB cervical carcinoma treated with pre-operative radio-chemotherapy, 
intracavitary brachytherapy, followed by extended radical hysterectomy.228
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Patients and Methods
Patients
From August 1991 to August 2005, 148 women, 
median age 48 years [21–88], were treated to the 
Institut Curie for operable FIGO Stage IB2 to IIB, 
biopsy proved carcinoma of the cervix. Among 
them, 70 patients, median age 46 years (range, 
24–80), were treated using the same regimen asso-
ciating primary radio-chemotherapy, intracavitary 
low dose rate brachytherapy, followed by extended 
radical hysterectomy and constitute the study 
population. Only 28 patients received concurrent 
chemotherapy and irradiation (RT-CT) before 1999 
as compared to 42 patients (60%) as from 1999.
All patients were clinically staged by the surgi-
cal oncologist as well as by the radiation oncologist, 
usually under general anaesthesia. All biopsies were 
reviewed for histology and viral study. All patients 
had to be previously untreated and presented his-
tologically conﬁ  rmed squamous cell carcinoma or 
adenocarcinoma of the uterine cervix.
Contrast-enhanced computerised tomography 
(CT) or more recently magnetic resonance imaging 
(MRI) of the pelvis and abdomen were used to 
determine the tumor spread and the nodal status. 
Last years, thoracic CT scan was added to the stag-
ing procedure.
All patients, before the treatment, required to 
meet all of the following laboratory criteria: hemo-
globin level  10 g/dL, WBC count  3000/mm
3, 
and/or absolute neutrophil count  1500/ mm
3, 
platelet count  100,000/mm
3, serum transaminase 
levels  60 IU/mL, total bilirubin level  1.5 mg/dL, 
serum creatinine level  1.5 mg/dL. Also deemed 
necessary was adequate cardiopulmonary function 
that could tolerate radical surgery.
Radiation modalities
Treatment protocol consisted of preoperative radio 
chemotherapy and intracavitary brachytherapy. 
Pelvic external beam radiotherapy (EBRT) was 
delivered using 18 to 20 MV photons and a 4-ﬁ  eld 
box technique, all treated every day. CT scan in 
treatment position was usually performed and 
patients underwent conformal RT in most cases. 
The superior limit was L4-L5, inferior included 
the vagina. Posterior limit was determined using 
pre-treatment CT scan. Median planned total dose 
was 36 Gy in 22 fractions of 1.8 Gy, ﬁ  ve days a 
week, following ICRU recommendations (14). All 
patients underwent weekly clinics and it was 
recommended to follow a low-ﬁ  bers diet, com-
bined with anti-spasmodic medication. Daily nurse 
care of the perineal skin was performed in the 
institution for all patients treated after 2000.
Brachytherapy procedure
Each brachytherapy procedure was performed 
under general anesthesia. The tumor regression was 
assessed by gynecologic examination after MRI 
and/or CT scan realized at the end of chemo-
radiotherapy. Depending on the length of the uterine 
cavity found during the brachytherapy procedure 
together with the topography of vagina and cervix 
as clinically evaluated, the appropriate size, length 
of the uterovaginal applicator of Delouche type was 
chosen as well as adapted sources of 
137Cesium. 
After implantation, orthogonal X-ray images were 
performed with a reconstruction jig. The dose dis-
tribution was based on anatomic, clinical and 
implant parameters. Low dose rate (LDR) brachy-
therapy was realized in all cases using Curithron 
machine with 137 Cs sources. The prescription was 
done to 60 Gy reference volumes. Nominal dose of 
30 Gy was delivered in reference volume, following 
ICRU recommendations (14).
Chemotherapy
Chemotherapy consisted of 5 Fluorouracil (5FU) 
600 mg/m² via continuous infusion and cisplatyl 
20 mg/m² from day 1 to day 5, starting concurrently 
with radiation therapy. The antiemetic regimen 
consisted of a combination of dexamethazone and 
5-hydroxytryptamine-3 antagonist. Two chemo-
therapy cycles were scheduled at 21 day-intervals. 
Routine blood cell counts and renal function tests 
were performed every week. No cytokine for aug-
menting granocyte colony growth was given.
Surgery
Six weeks after the completion of brachytherapy, 
all patients underwent radical hysterectomy, bilat-
eral adnexectomy, resection of a vaginal cuff. The 
ureters were separated from medial attachments to 
the peritoneum and the parametrial tissue was cut 
at the level of the ureters. Bilateral pelvic lymph-
adenectomy with node sample frozen section was 
routinely performed. In case of nodal involvement, 
lymphadenectomy was completed to the ipsilateral 
common iliac nodes.229
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Toxicity
Treatment toxicity was assessed weekly throughout 
the treatment period and scored according to the 
World Health Organization criteria. Acute side 
effects were those appearing during treatment. Late 
toxicity was the symptoms which appeared 6 
months after the completion of the treatment.
Statistical analysis
Kaplan-Meier estimates were used to draw survival 
curves. Survival rates are presented with their 95% 
conﬁ  dence interval. Comparisons of survival dis-
tribution were assessed by the log-rank test. p-value 
of less than 0.05 was considered as statistically 
signiﬁ  cant. Overall survival, relapse-free or distant 
free survivals were calculated from date of diagno-
sis to the date of local, regional or distant failure. 
Prognostic factors for local-regional or distant 
recurrences were assessed by univariate analysis. 
Prognostic factors were as follows, age at diagnosis 
(  = 45 versus  45), menopausal status, hemoglobin 
( 12 versus  /= 12), tumor size (5 cm vs.  5 cm), 
and stage (T1B2-IIa versus IIB), histological type 
(squamous vs. adenocarcinoma) and histological 
grade (well and moderate versus poor differentia-
tion), viral type (18–45 vs. 16 vs. others), clinical 
as well as pathologic nodal stage, pathologic 
response to treatment, chemotherapy doses. Due to 
the number of the study population, we did not 
intend to perform multivariate analysis.
Results
Patients
The studied population consisted of 70 patients 
FIGO Stage IB2 to IIB treated between August 
1991 and August 2005 primary radio-chemotherapy, 
intracavitary low dose rate brachytherapy, followed 
by radical hysterectomy. The median follow-up 
was 40 months (range 8–141 months).
Clinical and pathologic characteristics are 
shown in Table 1. Fifty of the patients (71%) were 
pre-menopausal. Sixty-eight patients (97.1%) 
presented normal weight and only 2 patients (3%) 
were obese. Only one patient had a history of 
diagnosis of previous cancer (breast). Median 
hemoglobin level at the diagnosis was 13 g/dl 
(range, 7–15). Fourteen patients (21.5%) presented 
haemoglobin levels  12 g/dl. Previous cervical 
Pap-smear test had been performed only in 
34 cases. The mean time interval between normal 
smear and diagnosis of cervical cancer was 18 
months.
Eighty three percent of the tumors were squa-
mous cell carcinomas, and 17% were adenocarci-
noma. Papilloma virus type (HPV) distribution is 
shown in Table 1.
Median clinical tumor size was 5 cm (range, 
2.9–10 cm). There were 23 (33%) tumor invasions 
to the upper vagina, and/or 40 (60%) to the proxi-
mal parametria. The clinical involvement of para-
metria was as follows: none in 30 cases (42.9%), 
unilateral in 32 pts (45.7%), bilateral in 8 cases 
(11.4%).
The median elapsed time between the ﬁ  rst diag-
nosis et the beginning of treatment was 3 
months.
Forty percent of the tumors were clinically 
Stage IB2-IIa and 60% were FIGO IIB.
Radiological abdominal and pelvic investiga-
tions consisted of CT scan in 25 patients (36%), 
of MRI in 18 patients (26%) and of both exams in 
27 patients (38%).
Totally, the imaging procedure depended from 
the year of treatment, as follows: 71.4% of all 
patients (50/70) underwent CT scan and 64.2% 
(45/70)—MRI.
Table 1. Patients’ characteristics (n = 70).
Patients’   N° of patients  %
characteristics
Histology  
 -  SCC  58  82.9
 -  Adenocarcinoma  12  17.1
Tumor differentiation   
 -  Well  42  61
 -  Moderate  14  19.5
 -  Poor  14  19.5
FIGO stage   
IB2 19  27.1
IIA 9  12.9
IIB 42  60
N stage (CT scan)   
N0 55  78.6
N1 pelvic  15  21.4
HPV status   
16 38  54.3
18 8  11.4
45 3  4.3
Other (31,33,35,53)  12  17.2
Unknown (Not done)  9  12.8230
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Investigations revealed radiological pelvic 
nodal involvement in 15 patients (21%). No 
patient had para-aortic suspicious node. All 
patients were free from clinical or radiological 
distant metastasis.
Radiation therapy
All patients completed the planned radiotherapy.
The median dose delivered to the pelvis was 36 
Gy (range, 35–38 Gy) in 20 fractions and 27 days 
(range 25–32). Intracavitary LDR brachytherapy 
was performed 10 days after the external beam 
radiotherapy (range 4–15 days). Nominal dose of 
30 Gy was delivered in reference volume. The 
mean dimensions of the 60 Gy reference volume 
were H = 10.5 cm, W = 7.5 cm, T = 6.5 cm, com-
bined with external beam radiotherapy. Median 
rectal and bladder nominal doses received from 
brachytherapy treatment, at reference points, were 
22 Gy (range, 8–36 Gy) and 13 Gy (range, 4–26 Gy), 
respectively.
Chemotherapy
All patients received at least one cycle of 
5-Fluorouracil-cisplatin chemotherapy. Because 
of hematological toxicity, 6 patients (8%) inter-
rupted their systemic treatment after one cycle of 
chemotherapy. Sixty-four (92%) patients received 
their 2 planned full-dose cycles of chemotherapy.
Compliance and acute toxicity
Early toxicity was usually mild and reversible 
(Table 2).
Due to hematological and/or gastrointestinal 
toxicity, radiation therapy was discontinued in 6 
patients. Four of those patients interrupted their 
treatment for one week and the two other patients 
for two weeks. Six patients (9%) received only one 
cycle of chemotherapy. In addition, 5 patients 
delayed their second cycle of chemotherapy: 4 with 
1 week and 1 patient with 2 weeks.
Grade 3 leucopenia and thrombocytopenia were 
observed in 10% and 13% of the patients, respec-
tively. Two patients presented Grade 4 leucopenia. 
Four patients underwent blood transfusion before 
the start of the treatment, but no further patient 
required transfusion during the combined protocol. 
All patients complained of severe fatigue (grade 3) 
during the three ﬁ  rst days following the administra-
tion of chemotherapy. Patients generally recovered 
spontaneously after four or ﬁ  ve days.
Table 2. Early concurrent chemo-radiotherapy toxic-
ity, (grade 4 is not mentioned in case of no grade 4 
toxicity).
Treatment toxicity  Pts  %
Anemia  
Grade 0  21  30
Grade 1  30  43
Grade 2  16  23
Grade 3  3  4
Leucopenia  
Grade 0  15  20.8
Grade 1  21  30.0
Grade 2  25  36.2
Grade 3  7  10.1
Grade 4  2  2.9
Thrombopenia  
Grade 0  30  43
Grade 1  15  21
Grade 2  16  23
Grade 3  9 13
Abnormal creatinine level  
Grade 0  68  97.2
Grade 1  1  1.4
Grade 2  0  0
Grade 3  1  1.4
Weight lost  
Grade 0  42  60.1
Grade 1  12  17.1
Grade 2  11  15.7
Grade 3  5  7.1
Skin and mucosal toxicity  
Grade 0  22  30.2
Grade 1  38  54.6
Grade 2  8  11.4
Grade 3  2  2.9
Diarrhea  
Grade 0  15  21.3
Grade 1  31  44.3
Grade 2  13  18.6
Grade 3  9  12.9
Grade 4  2  2.9
Alopecia  
Grade 0  57  81.4
Grade 1  11  15.7
Grade 2  2  2.9
No grade 3 and 4   
Infection  
Grade 0  59  84.3
Grade 1  3  4.2
Grade 2  4  5.8
Grade 3  3  4.2
Grade 4  1  1.5231
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Nausea and vomiting were very moderate: 
100% of patients presented grade 1 and 2 nausea 
and only one patient grade 2 vomiting.
Grade 3 and 4 diarrhea occurred 2 weeks after 
day 1 of chemo-radiotherapy and was signiﬁ  cantly 
increased after the administration of the 5 FU. 
Grade 2 gastro-intestinal disorders were observed 
at the fourth week of radiation therapy.
Due to intensive perineal nurse care, skin reac-
tion was generally limited to grade 1. Two patients 
only developed grade 3 skin reaction during the 
treatment.
Neurotoxicity and cardio toxicity occurred only 
in 1 patient (the same one).
A couple of patients developed grade 1 rectal 
bleeding after combined chemotherapy and radio-
therapy followed by brachytherapy. This symptom 
disappeared under local corticosteroid therapy. No 
patient presented any hematuria or ﬁ  stula.
Surgery
Surgery was performed 6 weeks (range, 5–11) after 
the brachytherapy. All patients underwent radical 
hysterectomy and pelvic external iliac lymphad-
enectomy. Ovaries had been transposed and pre-
served in 4 patients. In 8 cases, the frozen section 
revealed microscopic nodal involvement leading 
to extend lymphadenectomy. Among them, the 
lymphadenectomy was performed to ipsilateral 
common iliac lymph nodes in 3 patients and bilat-
eral common iliac nodes in 5 patients. In this group 
three patients underwent para-aortic lymphadenec-
tomy. The total mean number of examined lymph 
nodes was 10 (range 2–31, SD 5.45).
Pathologic response
Complete histological local-regional response was 
obtained in 56% of the patients (39 patients).
Residual macroscopic or microscopic disease 
in the cervix was observed in 28 patients (40%). 
All but one had in-situ microscopic residual car-
cinoma. Lateral residual disease in the parametria 
was also present in 9 patients, all with residual 
carcinoma of the cervix.
All patients but one had negative surgical margins.
Pelvic lymph nodes were free from microscopic 
disease in 56 patients (80%). Eight of 55 (11%) 
radiological N0 patients had microscopic nodal 
involvement, as compared to 6/15 (40%) radio-
logical N1 (p = 0.03). Seventeen patients (25%) 
had residual cervix disease but negative nodes.
Complications
No treatment-related death was observed. Despite 
anti-thrombosis safety treatment throughout 
brachytherapy and surgery, vein thrombosis 
occurred in two patients as well as pulmonary 
embolism in one patient. Ultrasound of the urinary 
tract was performed post-operatively in all patients. 
No ureteral ﬁ  stulae or bladder complication was 
observed.
Late toxicity
Four patients (5.7%) developed intestinal obstruc-
tion at 6 months (3 patients) and 96 months after 
the completion of surgery. Among them, 3 were 
treated medically and one surgically. In addition, 
one patient presented grade 3 proctitis. Two (3%) 
additional patients presented with grade 2 and 
grade 3 lymphedema of low extremities, respec-
tively. Four cases of vaginal necrosis (6%) occurred 
within six months following surgery.
Grade 3 pelvic sclerosis occurred in 2 heavy 
smokers. Twenty percent of the patients com-
plained of mild dyspareunia due to moderate 
shrinkage of the vaginal wall. When feasible, hor-
mone replacement treatment signiﬁ  cantly improved 
these disorders.
Survival
After median follow-up of 40 months (range, 
8–141), 38/70 patients (54.1%) are still alive and 
free of disease, 6 (8.6%) alive with disease, and 11 
(15.8%) patients were lost for follow-up (median 
follow-up: 25 months) but free of disease. Fifteen 
patients (21.5%) died, all but one from cervical 
cancer. No patient’s death was associated to treat-
ment complication.
Actuarial survival (Fig. 1) and disease-free 
survival (DFS) rates (Fig. 2) were as follows: 77% 
[95% conﬁ  dence interval [CI] 66–89] and 74% 
[95% CI: 63–85] at 3 years, and 77% [95% CI: 
66–89] and 68% [95% CI: 55–81] at 5 years, 
respectively.
Local-regional failures
Seven local failures occurred (10%), as follows: 
one patient presented massive pelvic recurrence 
with invasion of vagina, bladder, rectum, and lat-
eral pelvic wall 6 months after surgery. Another 
patient recurred in the low third of the vagina, and 
ﬁ  ve patients recurred in the parametria and pelvic 232
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lymph nodes within 18 months. Local failures were 
associated with para-aortic nodal recurrence in two 
cases and with distant failure in four cases.
Actuarial local and regional recurrence free 
survival rate was 90.5% [95% CI: 84–98] at 3 years 
and 87% [95% CI: 78–97] at 5 years.
Distant failures
Crude rate of para aortic and distant metastases 
was 25%. Twelve (67%) of the eighteen distant 
failures were not associated with a local and/or 
regional recurrence. Para-aortic lymph node 
failures were documented in 8 patients (11%). 
Among them, 3 were isolated, 2 were associated 
with pelvic nodal failure, and 3 with peritoneal 
recurrence. Five patients were diagnosed with 
isolated lung metastases.
Actuarial distant free survival rate was as fol-
lows 76% [95% CI: 66–87] at 3-years and 69% 
[95% CI: 57–84] at ﬁ  ve years.
Univariate analysis of prognostic 
factors for local or distant failure
As previously shown, numerous prognostic factors 
have been studied using univariate analysis; the 
results are shown in Table 3. Due to the small 
numbers of patients, we did not intend to perform 
to a multivariate analysis.
In univariate analysis, pathological nodal inva-
sion was the only prognostic factor for survival. The 
actuarial survival rate at three years was 81% ± 6 in 
node negative patients as compared to 60% ± 14 in 
node positive patients ( p = 0.05) (Fig. 3). Similarly, 
radiological or pathological pelvic nodal invasion 
were significant prognostic factors for local 
( p = 0.001) and for distant failure ( p = 0.001).
Clinical tumor size or stage as well as any 
residual tumor on surgical specimen did not show 
any signiﬁ  cant inﬂ  uence on local or distant failure 
rates. This was conﬁ  rmed by subgroup analyses 
looking at pathological results in terms of node 
negative associated or not with residual local tumor. 
Again, the presence of carcinoma in pelvic nodes 
remains the only prognostic factor for failure.
Discussion
The presented experience shows that with respect 
of Institution’s protocols and the work of an 
experimented team of specialists, the results in 
terms of tumor response, DFS, overall survival, 
and also in toxicity are comparable with the previ-
ously published controlled trials. This speciﬁ  c 
scheme, combining lower dose of EBRT (36 Gy) 
and higher dose of brachytherapy (30 Gy), com-
bined with surgical resection encompassing the 
proximal part of the parametrial tissue, shows 
good loco-regional control and survival, accepted 
late and early toxicity, and quality of life of our 
patients. Furthermore, no urinary complication 
was observed in this study population, whereas 
other studies reported 9% (6) 15% (15), and 
Figure 1. Overall (Kaplan-Meier) survival curve.
Figure 2. Disease-free (Kaplan-Meier) survival curve.
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Table 3. Pre-operative concurrent radiation and chemotherapy: survivals.
Variable # of 
patients
3-year 
survival 
%
p-value 3-year 
LRFS
1 
%
p-value 3-year 
DRFS
2 
%
p-value 3-year 
DFS
3 
%
p-value
Age at diagnosis NS NS NS NS
 45 34 77 ± 89 1  ± 57 8  ± 77 8  ± 7
 45 36 78 ± 88 9  ± 67 2  ± 99 9  ± 9
Menopause NS NS NS 0.02
Yes 20 82 ± 69 4  ± 38 2  ± 68 2  ± 6
No 50 67 ± 12 87 ± 10 60 ± 12 57 ± 4
Hemoglobin NS NS NS NS
 12 16 81 ± 12 93 ± 76 4  ± 15 64 ± 15
 12 54 73 ± 78 9  ± 57  ± 67 5  ± 6
Clinical T stage NS NS NS
TIB2 19 83 ± 10 90 ± 78 4  ± 88 4  ± 8
T2a 9 83 ± 10 100 75 ± 15 78 ± 15
T2b 42 74 ± 88 9  ± 67 3  ± 77 0  ± 8
Clinical T stage NS NS NS NS
T1B2-T2a 28 83 ± 99 3  ± 58 2  ± 78 2  ± 7
T2b 42 73 ± 78 9  ± 57 2  ± 77 1  ± 8
Tumor size NS NS NS NS
 5 cm
 5 cm
Clinical N stage NS NS NS NS
N0 55 77 ± 69 4  ± 37 7  ± 67 6  ± 6
N1 15 77 ± 12 79 ± 11 71 ± 12 71 ± 12
Histology NS NS NS NS
Squamous 58 76 ± 59 0  ± 47 6  ± 67 4  ± 6
Glandular 12 78 ± 14 92 ± 87 5  ± 12 75 ± 12
Differentiation NS NS NS NS
Well 43 79 ± 78 9  ± 58 0  ± 78 0  ± 7
Mean-poor 27 74 ± 99 3  ± 57 2  ± 96 8  ± 9
HPV
4 NS NS NS NS
Not done 9 75 ± 15 87 ± 12 100 87 ± 12
18–45 11 58 ± 18 91 ± 97 3  ± 13 73 ± 13
16 38 80 ± 79 2  ± 57 3  ± 87 3  ± 8
Other 12 81 ± 12 91 ± 97 5  ± 12 75 ± 12
Path. node 
status
5
0.05 0.001 0.004 0.004
Negative nodes 56 85 ± 69 8  ± 28 4  ± 58 4  ± 5
Positive nodes 14 60 ± 14 99 ± 13 49 ± 13 49 ± 13
Path. Report
5 NS 0.002 0.005 0.009
R0
6 39 86 ± 6 100 90 ± 59 0  ± 5
negative nodes
and residual cells 17 82 ± 12 93 ± 67 1  ± 13 71 ± 13
Positive nodes 14 60 ± 14 69 ± 13 49 ± 14 49 ± 14
1Local recurrence-free survival. 
2Distant recurrence-free survival. 
3Disease-free survival. 
4Papilloma virus type. 
5Pathological.234
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20% (17) of urinary complications with external 
radiation dose of 45 Gy.
In our study we found 3-years actuarial survival 
and disease-free survival (DFS) rates respectively 
of: 77% [95% CI] 66–89] and 74% [95% CI: 
63–85]. Corresponding scores at 5 years were 77% 
[95% CI: 66–89] and 68% [95% CI: 55–81]. These 
results are similar to the reported results of large 
controlled studies (7).
Nine reports of randomized trials of concurrent 
cisplatin-based chemoradiotherapy and one meta-
analysis showed that this treatment improves over-
all survival over various controls in women with 
locally advanced cervical cancer (3–12). The varia-
tion of chemotherapy protocols, different extent of 
surgical management and radiotherapy modalities 
among the published trials make interpretation dif-
ﬁ  cult (3–13). Therefore the aim of our study was to 
report an objectively homogeneous population of 
patients, treated with the same chemo-and radiation 
therapy regiment, operated by the same surgeon 
team, and to try to ﬁ  nd any prognostic factors.
Surgical resection allows assessment of patho-
logical response and can improve treatment out-
come in the case of a partial pathological response. 
In the current study, the rate of complete patho-
logical response after chemoradiotherapy (36 Gy) 
and brachytherapy (30 Gy), as determined based 
on the analysis of surgically removed tissues, was 
56%. Recently, in a multicenter study of surgery 
after concurrent chemoradiotherapy (45 Gy) and 
brachytherapy (15 Gy) for the treatment of 
advanced cervical cancer, a pathological complete 
response was reported in 39% of patients (67/175) 
(15). Other studies reported a complete patho-
logical response rates of 52% to 54,2% could be 
obtained with preoperative chem oradiotherapy 
(45 Gy, 39.6 Gy) in stage IB2-IIIA cervical cancer 
(6, 16). Jurado et al. reported a complete response 
rate of 67.5% (27/40) in a series of patients treated 
with concurrent chemoradiotherapy (45 Gy), sur-
gery, and intra-operative radiation therapy (17).
Recently, the importance of surgical resection 
was also shown in the study of the GCCLCC (15). 
The authors studied 175 patients treated by neoad-
juvant chemoradiotherapy, followed by surgical 
resection. At a median follow-up of 36 months, after 
hysterectomy, the authors reported an acceptable 
morbidity and concluded that surgery allows an 
evaluation of the pathological response to previous 
treatment and improves local control in the case of 
partial pathological response (15). In addition, as 
conclusion of our experience, after radical hyster-
ectomy and pelvic external iliac lymphadenectomy, 
it is possible in case of positive lymph nodes to add 
adapted to every case adjuvant treatment. Recently 
published paper (18) showed 16% lymph node 
involvement after chemoradiation and concluded 
that performing a pelvic lymphadenectomy along 
with the removal of the primary tumor after neo-
adjuvant treatment could reduce the rate of latero-
pelvic recurrences. This study supports our 
treatment strategy of larger surgical resection after 
chemoradiation therapy. To decrease the side effects 
after treatment and to approve the quality of life in 
our patients’ population, this radiochemotherapy 
regimen proposes a good compromise between the 
volumes and doses of EBRT and brachytherapy. 
The adverse effects of this regimen were exclu-
sively transient, comparable with those of other 
studies. This regimen can be better tolerated 
because of the only 2 provided cycles of chemo-
therapy. Kirwan et al. (19) have studied 4580 
patients in 19 randomized studies and they showed 
that more than 1 in 10 patients suffered severe or 
potentially life-threatening complications in the 
chemoradiation arms, more than twice as many as 
in the control group. All factors have been studied: 
complications of surgery, of radiation therapy (bone 
marrow included in the radiation ﬁ  eld), and side 
effects of chemotherapy treatment. At the other 
hand, late toxicity and quality of life are two issues, 
not always debated in the results of randomized 
trials. As conclusion, the authors reported that in 
Figure 3. Disease-free survival curve according to pathological 
T and N response.
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view of the consistency and extent of the survival 
beneﬁ  t for chemo radiation the additional acute 
toxicity is justiﬁ  ed. The authors suggested that all 
studies should systematically collect chronic toxic-
ity data using a standard data collection form such 
as the revised common toxicity criteria (19).
This homogeneous single institutional retrospec-
tive study showed a high rate of pathologic response 
and local control as well as no urinary morbidity in 
patients with advanced cervical undergoing moder-
ate dose of radiotherapy with concomitant chemo-
therapy followed by radical surgery. It shows also 
the comparable results with other studies, as well 
as the advantages of a good multidisciplinary 
approach in the treatment of cervical cancer. How-
ever, this study must be the step to the development 
of new protocols and techniques in our every day 
practice. Based on previously published studies, 
the concurrent chemotherapy is already a routine 
part of our treatment (20). To improve the treatment 
tolerance, currently weekly Cisplatin scheme is 
used, as recommended. In the same time, new treat-
ment modalities are being developed by our team. 
Based on the recently published data of Bonner 
et al. (21), a new protocol is currently submitted 
for discussion, comparing weekly Cisplatin and 
radiation therapy to Cisplatin plus Cetuximab and 
radiotherapy. Testing this new approach, we hope 
to improve the treatment results. Furthermore, the 
development of new techniques of radiation ther-
apy, as intensity modulating radiation therapy 
(IMRT), could decrease early and/or late effects of 
RT. It may also improve the treatment results by 
means of dose escalation and when needed by 
including the para-aortic lymph nodes in the treated 
volume, without increasing the toxicity of this large 
irradiation ﬁ  eld (22). Parallel to these improvement 
in our treatment protocols, serious work is running 
in the development of new vaccines against the 
cervical HPV infection.
The treatment of locally advanced cervical 
cancer needs a new multidisciplinary diagnostic 
and treatment approach using new therapeutic arms 
to improve the survival and treatment tolerance 
among women presenting this disease.
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